Drugs / HSK29116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04861779 | Aug 2021 → Aug 2023 | B-cell non-Hodgkin lymphoma | Haisco Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK29116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04861779 ↗ |
| Route | Oral | “Oral HSK29116” NCT04861779 ↗ |
| Target | BTK | “BTK Protein Degradation Agent HSK29116” NCT04861779 ↗ |